Suppressing the growth of rectal cancer xenografts derived from patient tumors by an adenovector expressing small hairpin RNA targeting Bcl-XL

Journal of Gene Medicine

Volumn 14, Issue 12, 2012, Pages 761-768

  Zhu, Hongbo ^a   Zhou, Wei ^a   Hu, Jingzi ^b   Huang, Zhongting ^a   Lao, Weifeng ^a   Huang, Xuefeng ^a   He, Chao ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Department of Internal Medicine   (China)

Author keywords

Adenovirus; Bcl XL; Rectal cancer; Small hairpin RNA; Xenograft

Indexed keywords

ADENOVIRUS VECTOR; FLUOROURACIL; PROTEIN BCL XL; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECTUM CANCER; SURVIVAL TIME;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; BCL-X PROTEIN; GENE EXPRESSION; GENETIC VECTORS; HUMANS; MICE; MICE, NUDE; RECTAL NEOPLASMS; RNA, SMALL INTERFERING; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE;

EID: 84871518750     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2681     Document Type: Article

References (25)

1. Gottlieb E, Vander Heiden MG, Thompson CB. Bcl-x(L) prevents the initial decrease in mitochondrial membrane potential and subsequent reactive oxygen species production during tumour necrosis factor alpha-induced apoptosis. Mol Cell Biol 2000; 20: 5680-5689.
2. Zhang L, Yu J, Park BH, et al. Role of BAX in the apoptotic response to anticancer agents. Science 2000; 290: 989-992.
3. Zangemeister-Wittke U, Leech SH, Olie RA, et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumour cells. Clin Cancer Res 2000; 6: 2547-2555.
4. Hinz S, Trauzold A, Boenicke L, et al. Bcl-XL protects pancreatic adenocarcinoma cells against. Oncogene 2000; 19: 5477-5486.
5. Zhu H, Guo W, Zhang L, et al. Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther 2005; 4: 451-456.
6. Zhu H, Guo W, Zhang L, et al. Enhancing TRAIL-induced apoptosis by Bcl-X(L) siRNA. Cancer Biol Ther 2005; 4: 393-397.
7. Zhu H, Zhu Y, Hu J, et al. Adenovirus-mediated small hairpin RNA targeting Bcl-XL as therapy for colon cancer. Int J Cancer 2007; 121: 1366-1372.
8. Giovanella BC, Yim SO, Stehlin JS, et al. Development of invasive tumours in the 'nude' mouse after injection of cultured human melanoma cells. J Natl Cancer Inst 1972; 48: 1531-1533.
9. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature 1983; 301: 527-530.
10. Jin K, Teng L, Shen Y, et al. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol 2010; 12: 473-480.
11. Morton CL, Houghton PJ. Establishment of human tumour xenografts in immunodeficient mice. Nat Protoc 2007; 2: 247-250.
12. Marangoni E, Vincent-Salomon A, Auger N, et al. A new model of patient tumour-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007; 13: 3989-3998.
13. Zhou W, Zhu H, Chen W, et al. Treatment of patient tumour-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus. Cancer Gene Ther 2011; 18: 336-345.
14. Rocha JA. Bevacizumab in combination with irinotecan, 5-fluorouracil and leucovorin given as first-line treatment of metastatic colorectal cancer. Anticancer Drugs 2011; 22(Suppl 2): S9-S13.
15. Fichtner I, Slisow W, Gill J, et al. Anticancer drug response and expression of molecular markers in early passage xenotransplanted colon carcinomas. Eur J Cancer 2004; 40: 298-307.
16. Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 2004; 40: 837-844.
17. Grem JL. 5-Fluoropyrimidines. In Cancer Chemotherapy and Biotherapy, Chabner BA, Longo DL (eds). Lippincott-Raven: Philadelphia, PA, 1996; 149-211.
18. Chau I, Cunningham D. Chemotherapy in colorectal cancer: new options and new challenges. Br Med Bull 2002; 64: 159-180.
19. van Triest B, Pinedo HM, van Hensbergen Y, et al. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res 1999; 5: 643-654.
20. Arnold CN, Goel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 2003; 106: 66-73.
21. Violette S, Poulain L, Dussaulx E, et al. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer 2002; 98: 498-504.
22. Liu R, Page C, Beidler DR, et al. Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumours in a syngeneic mouse model. Am J Pathol 1999; 155: 1861-1867.
23. Shi X, Liu S, Kleeff J, et al. Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002; 62: 354-362.
24. Zhu H, Zhang L, Huang X, et al. Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. Mol Ther 2004; 9: 666-673.
25. Benihoud K, Esselin S, Descamps D, et al. Respective roles of TNF-alpha and IL-6 in the immune response-elicited by adenovirus-mediated gene transfer in mice. Gene Ther 2007; 14: 533-544.